ImmuPharma (LON:IMM) Trading Up 12.7% – Time to Buy?

ImmuPharma plc (LON:IMMGet Free Report) was up 12.7% on Friday . The stock traded as high as GBX 4.50 ($0.06) and last traded at GBX 4.06 ($0.05). Approximately 30,253,918 shares traded hands during mid-day trading, an increase of 54% from the average daily volume of 19,606,457 shares. The stock had previously closed at GBX 3.60 ($0.04).

ImmuPharma Stock Performance

The stock has a market capitalization of £16.39 million, a P/E ratio of -393.60 and a beta of 1.53. The stock has a 50-day moving average price of GBX 1.75 and a two-hundred day moving average price of GBX 1.73.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Further Reading

Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.